In March, the ACR released a white paper designed primarily to help rheumatologists and rheumatology health professionals gain an understanding of biosimilars.1 This research-based education piece examines the scientific, economic and prescribing issues related to the use of biosimilars. Now, the ACR has released an update to its official position statement on the use of…
ACR Puts Forward Principles on Patient Access to Care
As the 115th Congress and the Trump administration consider potential reforms to the healthcare system, including actions related to the Affordable Care Act (ACA), physicians around the country remain vitally concerned about the need to preserve and improve access to care for their patients. To that end, the ACR continues to lobby for policies that…
ACR Releases New Position Statements on Site of Service & Compounding
Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…